Full-Time

Sr. Associate Scientist

Upstream Polysaccharide Process Development

Confirmed live in the last 24 hours

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Biotechnology
Healthcare

Compensation Overview

$111k - $128kAnnually

Senior

San Carlos, CA, USA

Position is onsite in San Carlos, California.

Category
Computational Biology
Genomics
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Python
R
Word/Pages/Docs
Excel/Numbers/Sheets
Requirements
  • MSc in Chemical/Biochemical Engineering, Biotechnology, or similar degree with a minimum of 3 years of relevant industry experience, or BSc with a minimum of 5 years of relevant industry experience.
  • Experience in handling microorganisms with proper aseptic techniques to perform upstream processing related work in flasks/bioreactors.
  • Hands-on experience and theoretical understanding of key processing operations such as microbial culture, fermentation process, microbial media, and process optimization and relevant analytical technologies; experience with depth filtration, continuous centrifugation is a plus.
  • Develop and optimize scripts for instrumentation, including Ambr® systems, to enhance efficiency and automate processes, leveraging programming languages such as Python or R is a plus.
  • Experience with Design of Experiments (DoE) principles and DoE software.
  • Process characterization experience is a plus.
  • Cell banking expertise, colony selection and genetic analysis of recombinant strains is a plus.
  • Proficiency with computer programs such as Microsoft Excel, Word, PowerPoint, Visio and JMP.
  • Working knowledge of GMP requirements.
  • Proven ability to succeed in a cross-functional team environment, effectively managing multiple projects and contributing to team outcomes.
  • Strong interpersonal skills, with excellent written and verbal communication abilities.
Responsibilities
  • Support in study design, execute, and analyze experiments for upstream polysaccharide for bacterial fermentation (BSL2) and vaccine production processes.
  • Execute experiments to develop the upstream process parameters (e.g., media, feed, pH, temperature, dissolved oxygen, agitation, etc.) and to enhance product yield, quality, and consistency.
  • Perform microbiology related work including plating, colony selection, Gram staining and cell enumeration on microscope.
  • Perform fermentation vessel assembly and script writing for process automation and execute fermentation experiment in shake-flask and lab scale bioreactors.
  • Prepare media and buffer as needed for experiments.
  • Operate and maintain instrumentation for bacterial fermentation and primary recovery (centrifugation, filtration, etc.) of bacterial polysaccharides utilizing aseptic techniques.
  • Support analytical method execution including optical density, residual metabolites and polysaccharide concentration and other relevant analytical techniques.
  • Assist in executing late-stage process development studies including process characterization.
  • Keep accurate and current records of research and/or project related activities in laboratory notebooks and Electronic Lab Notebook.
  • Prepare and review protocol, technical reports, SOPs, and batch records.
  • Present and communicate scientific data and results to internal stakeholders.
  • Be an outstanding teammate and collaborate effectively with downstream, analytical, and manufacturing teams within Polysaccharide Development and Manufacturing team to ensure seamless technology transfer and process integration.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA for adult use. Vaxcyte employs advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while eliciting a strong immune response. Unlike traditional cell-based methods, their approach allows for the development of broad-spectrum vaccines. Vaxcyte's goal is to provide effective vaccines that can significantly reduce the impact of bacterial infections on global health.

Company Stage

IPO

Total Funding

$273.3M

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

23%

1 year growth

61%

2 year growth

132%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from major financial entities like Vanguard and Mutual of America Capital Management indicate strong market confidence in Vaxcyte's potential.
  • The recent $816.5 million raised through stock and warrant sales provides substantial capital for advancing their vaccine pipeline.
  • The appointment of experienced board members like John Furey can provide strategic guidance and enhance corporate governance.

What critics are saying

  • The success of Vaxcyte heavily depends on the clinical and commercial success of its lead product, VAX-24, which is still subject to regulatory approval.
  • The competitive landscape in vaccine development is intense, with numerous established players potentially overshadowing Vaxcyte's market entry.

What makes Vaxcyte unique

  • Vaxcyte leverages its proprietary XpressCF™ cell-free protein synthesis platform, which allows for more efficient and versatile vaccine production compared to traditional cell-based methods.
  • Their focus on broad-spectrum vaccines, such as VAX-24 targeting 24 strains of Streptococcus pneumoniae, sets them apart in the vaccine development landscape.
  • The FDA Breakthrough Therapy designation for VAX-24 underscores the innovative potential and clinical significance of their lead product.

Help us improve and share your feedback! Did you find this helpful?